Full history for every metric is available with a Kvantra account
89bio, Inc. (ETNB)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -385 | -466 | |||||
| Net profit | $m | -57 | -49 | -90 | -102 | -142 | -367 | -450 |
| EPS reported | $ | -3.51 | -3.61 | |||||
| Operating cashflow per share | $ | -3.51 | -1.09 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -3.51 | -1.09 | |||||
| Free cash flow | $m | -368 | -439 | |||||
| Net debt | $m | -404 | -525 | |||||
| Book value equity | $m | 401 | 522 | |||||
| Book value per share | $ | 3.83 | 3.30 | |||||
| Number of shares | m | 104.71 | 157.88 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 2.04 | 4.22 | |||||
| P/S LTM | x | 0.00 | 104,798.07 | |||||
| P/FCF LTM | x | -2.23 | -5.01 | |||||
| EV/EBITDA LTM | x | -1.90 | -3.76 | |||||
| EV/Sales LTM | x | 0.00 | 79,797.69 | |||||
| Earnings Yield LTM | % | -44.83% | -7.80% | |||||
| FCF Yield | % | -44.92% | -19.96% | |||||
| Quality | ||||||||
| ROE | % | -91.59% | -32.43% | |||||
| ROIC | % | -86.77% | -33.96% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | -91.03% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -9.80 | -11.67 | |||||
| Net Debt/EBITDA | x | 0.23 | 0.50 | |||||
| EBIT/Net interest | x | -101.57 | -79.76 | |||||
| Net debt/market cap | % | -49.36% | -23.86% | |||||
| Net debt/Equity | x | -1.01 | -1.01 | |||||
| Gross debt/equity | x | 0.09 | 0.07 | |||||
Company overview
Operating as a clinical-stage biopharmaceutical company, 89bio, Inc. is dedicated to advancing and commercializing therapeutic solutions for ailments impacting the liver and metabolic system. Their flagship product candidate, pegozafermin, is a modified fibroblast growth factor 21 (FGF21) analog specifically designed to address nonalcoholic steatohepatitis (NASH). Furthermore, the company has plans to explore pegozafermin's utility in treating severe hypertriglyceridemia. Founded in 2018, 89bio, Inc. maintains its corporate headquarters in San Francisco, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
89bio, Inc. (ETNB)
Operating as a clinical-stage biopharmaceutical company, 89bio, Inc. is dedicated to advancing and commercializing therapeutic solutions for ailments impacting the liver and metabolic system. Their flagship product candidate, pegozafermin, is a modified fibroblast growth factor 21 (FGF21) analog specifically designed to address nonalcoholic steatohepatitis (NASH). Furthermore, the company has plans to explore pegozafermin's utility in treating severe hypertriglyceridemia. Founded in 2018, 89bio, Inc. maintains its corporate headquarters in San Francisco, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free